MAP2K7 and central nervous system cancer: Patients with glioma harboring BRAFV600E might benefit from MAPK pathway inhibitor target therapy, a rescue treatment that includes the use of RAF inhibitors and MEK inhibitors alone or in combination (38–41), and the results were encouraging (42).